Benzocaine-induced methemoglobinemia in dogs.
Methemoglobinemia developed in three dogs after the owners' use of benzocaine-containing products for topical treatment of the dogs' pruritic skin conditions. The products were intended for use in man. In two of the dogs, clinical signs of shock were observed within a few hours after the application of a skin lotion containing 5% benzocaine. Methemoglobin was assayed in one case and found to be 51% of total hemoglobin. Both dogs recovered after whole blood transfusions were given. The third dog, which had been treated for several weeks with small amounts of an anesthetic aerosol containing 20% benzocaine, was anorectic and lethargic when examined. Methemoglobin content was 30%, and Heinz bodies were observed in 20% of the erythrocytes. The methemoglobin content and proportion of Heinz bodies decreased rapidly after use of the spray was discontinued. The two benzocaine-containing products incriminated in development of the methemoglobinemia did not induce measurable increases in methemoglobin content in clinically normal dogs, when applied to unbroken skin. Small increases in methemoglobin content were measured, however, when these products were given orally to clinically normal dogs. It was concluded that the skin lesions in the three clinically affected dogs enhanced absorption of the drug, resulting in methemoglobin formation.
D000818:Animals; D001205:Ascorbic Acid / Q000627:therapeutic use; D001566:Benzocaine / Q000009:adverse effects* / Q000378:metabolism / Q000627:therapeutic use; D004283:Dog Diseases / Q000139:chemically induced* / Q000188:drug therapy; D004285:Dogs; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D008297:Male; D008708:Methemoglobinemia / Q000139:chemically induced / Q000188:drug therapy / Q000662:veterinary*; D008751:Methylene Blue / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy / Q000662:veterinary
D001205:Ascorbic Acid; D008751:Methylene Blue; D001566:Benzocaine